Success Metrics

Clinical Success Rate

91.7%

Based on 11 completed trials

Completion Rate

92%(11/12)

Active Trials

1(7%)

Results Posted

55%(6 trials)

Terminated

1(7%)

Phase Distribution

Ph phase_2

21%

Ph phase_1

79%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution14 total trials

Phase 1Safety & dosage

11(78.6%)

Phase 2Efficacy & side effects

3(21.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

84.6%

11 of 13 finished

Non-Completion Rate

15.4%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(11)

Terminated(2)

Detailed Status

Completed11

Active, not recruiting1

Terminated1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

91.7%

Most Advanced

Phase 2

Trials by Phase

Phase 111 (78.6%)

Phase 23 (21.4%)

Trials by Status

completed1179%

active_not_recruiting17%

terminated17%

withdrawn17%

Recent Activity

1 active trials

Showing 5 of 14

completedphase_1

INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

NCT04398433

active_not_recruitingphase_1

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

NCT04367675

completedphase_2

Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers

NCT04588428

completedphase_1

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

NCT03502785

completedphase_1

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

NCT03835533

View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials

NCT04398433Phase 1

INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

Completed

NCT04367675Phase 1

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

Active Not Recruiting

NCT04588428Phase 2

Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers

Completed

NCT03502785Phase 1

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Completed

NCT03835533Phase 1

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

Completed

NCT04642638Phase 2

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

Terminated

NCT03831503Phase 1

A Study of INO-A002 in Healthy Dengue Virus-naive Adults

Completed

NCT03180684Phase 2

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Completed

NCT03606213Phase 1

Therapeutic Vaccination in Treated HIV Disease

Completed

NCT04093076Phase 1

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana

Completed

NCT05430958Phase 1

Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers

Withdrawn

NCT04447781Phase 1

Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19

Completed

NCT04336410Phase 1

Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers

Completed

NCT03805984Phase 1

Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers

Completed

All 14 trials loaded

Drug Details

Intervention Type: DEVICE
Total Trials: 14